Rhythm Pharmaceuticals (NASDAQ:RYTM) was upgraded by investment analysts at BidaskClub from a “sell” rating to a “hold” rating in a note issued to investors on Wednesday, March 14th.
RYTM has been the subject of several other reports. Cowen restated a “buy” rating and issued a $40.00 price objective on shares of Rhythm Pharmaceuticals in a research note on Tuesday, November 14th. Needham & Company LLC restated a “buy” rating and issued a $32.00 price objective on shares of Rhythm Pharmaceuticals in a research note on Monday, February 26th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $31.25.
NASDAQ RYTM traded down $0.73 on Wednesday, reaching $19.46. The company had a trading volume of 87,759 shares, compared to its average volume of 110,922. The company has a market capitalization of $530.95 and a PE ratio of -6.88. Rhythm Pharmaceuticals has a 52 week low of $16.80 and a 52 week high of $33.81.
Rhythm Pharmaceuticals (NASDAQ:RYTM) last posted its earnings results on Monday, March 12th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.14. equities research analysts predict that Rhythm Pharmaceuticals will post -2.3 EPS for the current year.
Large investors have recently modified their holdings of the stock. Wells Fargo & Company MN acquired a new stake in shares of Rhythm Pharmaceuticals in the 4th quarter valued at $131,000. American International Group Inc. acquired a new stake in shares of Rhythm Pharmaceuticals in the 4th quarter valued at $161,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Rhythm Pharmaceuticals in the 4th quarter valued at $184,000. Metropolitan Life Insurance Co. NY acquired a new stake in shares of Rhythm Pharmaceuticals in the 4th quarter valued at $196,000. Finally, MetLife Investment Advisors LLC acquired a new stake in shares of Rhythm Pharmaceuticals in the 4th quarter valued at $287,000. 89.91% of the stock is currently owned by institutional investors and hedge funds.
WARNING: “Rhythm Pharmaceuticals (NASDAQ:RYTM) Rating Increased to Hold at BidaskClub” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another site, it was stolen and republished in violation of United States and international copyright law. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/04/08/rhythm-pharmaceuticals-rytm-lifted-to-hold-at-bidaskclub.html.
Rhythm Pharmaceuticals Company Profile
Rhythm Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. The Company’s lead peptide product candidate is setmelanotide, a potent, first-in-class melanocortin-4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity.
Receive News & Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.